2017 Chinese pharmaceutical companies | 'Transcripts': cross-border mergers and acquisitions into a red net | preparation export performance mediocre
Go abroad, competing for the international market, is the dream of many pharmaceutical companies.Now, whether this dream has been shines into reality?
On February 6, 2018, the data released by China Chamber of Commerce for Import and Export of Medicines and Health Products (the 'Medicare Chamber of Commerce') showed that in 2017, the exports of Chinese and Western medicinal products both rebounded to 3.64 billion U.S. dollars and 35.456 billion yuan Dollars.
Of the transcripts, bulk pharmaceutical exports still contributed the bulk with a total export volume of 29.117 billion U.S. dollars, accounting for nearly three-quarters of all exports.
It can be said that the export of pharmaceutical companies in China did not show any remarkable performance in 2017. However, there are indications that many enterprises have already accumulated their 'kinetic energy'.
In its summary of the trends and characteristics of 2017, the health care providers' lack of 'good news' on the export of indigenous products.
In contrast, the Medicare Chamber of Commerce summarized the characteristics of China's pharmaceutical exports in 2016 when it said that 'local enterprises' export preparations performed well.'
Among the western medicine products, the export of western medicine products increased by 8.32% from the same period of last year to reach 3.456 billion U.S. dollars in 2017. The growth of this data was mainly driven by the growth of export preparations of foreign pharmaceutical enterprises in China, Than the basic flat, there is no stunning performance.
However, the "momentum" of Chinese pharmaceutical companies' savings in 2017 attracted attention and completed a number of cross-border mergers and acquisitions, the CICC quoted Ezinenet data as showing that in the first three quarters of 2017, in the case of cross-border mergers and acquisitions by Chinese enterprises, Occupying 13% of the healthcare sector, 32 cases of cross-border mergers and acquisitions were completed, up from 21 cases in the same period of 2016, involving an amount of 4.7 billion U.S. dollars.
At the beginning of 2017, the Sanpower Group announced that it will acquire US biopharmaceutical company Dendreon for 819 million U.S. dollars. After that, Fosun Pharma, Human Health Pharmaceutical, Xianju Pharmaceutical, Sansheng Pharmaceutical and the Viagra Group have all made their debut. Fosun Pharma, the first overseas biopharmaceutical company to record a record high of 1.091 billion U.S. dollars, has so far set itself the largest overseas acquisition by Chinese pharmaceutical companies.
Highlights Also, in 2017, Chinese pharmaceutical companies had 34 pharmaceutical products that received the ANDA (eight of which were tentatively approved), which is 1.7 times the number approved in 2016.
Foreign acquisitions, ANDA number approved, not yet 'blessing' Western medicine exports .Medicine and Health Chamber of Commerce Meng Dongping accepted an interview with the "Financial" reporter said that the domestic pharmaceutical enterprises to go out in the form of diversification is being achieved, in addition to cross-border Mergers and acquisitions, application numbers to promote the export of preparations, processing trade, medical services trade has also become an effective way to 'go out'.
Since 2017, 'Licensing' has become the key word in the field of pharmaceutical research and development in China. The six products of Baekje, Hengrui Medicine, Yuheng Pharmaceutical and Nanjing Legends are licensed with overseas research and development giants, Multinational investment banks to cooperate, the total amount of transactions exceeded 3.2 billion US dollars.
Data from the CSPC show that the processing trade of Chinese pharmaceutical enterprises has increased by 48.80% in 2017; the new formats of CRO (Pharmaceutical R & D Contract Outsourcing), CMO (Pharmaceutical Production Contract Outsourcing) and CSO (Pharmaceutical Sales Contract Outsourcing) Pharmaceutical companies participate in the new form of international division of labor.
'The pharmaceutical and international trade environment has been generally favorable with the recovery in the major markets such as the United States, the European Union and India and the steady growth expected.' 'Meng Dongping predicts that the fundamentals for the steady development of pharmaceutical foreign trade will continue in 2018.
Despite the fact that Chinese pharmaceutical companies have taken the "good" transcripts, the innovation and research and development that underpin their dreams are still slowing the pace of "going global." The overall innovation capability still needs to be improved.
After investigating some economic and technological development zones, medical industrial parks and related enterprises in China, the medical insurance providers still found that the problems of insufficient investment and serious homogenization of enterprise products still exist, for example, the R & D expenditure of some enterprises is even lower than the total sales revenue of 1 %, Do not have R & D and innovation capabilities; part of the Economic Development Zone, Industrial Park is located in the Midwest, R & D capabilities and resources are relatively weak, independent intellectual property rights and less well-known brands, innovative leaders rare.
R & D is a systematic project that requires interdisciplinary scientists to work together. 'R & D of pharmaceutical companies is not just a few scientists from abroad, how many rounds of financing they can get out.' "Novartis (China) Zhao Yan, vice president of medical affairs, said at a recent conference.
